BR112018073945A2 - métodos para tratamento de miastenia grave generalizada refratária - Google Patents

métodos para tratamento de miastenia grave generalizada refratária

Info

Publication number
BR112018073945A2
BR112018073945A2 BR112018073945-6A BR112018073945A BR112018073945A2 BR 112018073945 A2 BR112018073945 A2 BR 112018073945A2 BR 112018073945 A BR112018073945 A BR 112018073945A BR 112018073945 A2 BR112018073945 A2 BR 112018073945A2
Authority
BR
Brazil
Prior art keywords
myasthenia gravis
methods
treating refractory
generalized myasthenia
refractory generalized
Prior art date
Application number
BR112018073945-6A
Other languages
English (en)
Inventor
Bedrosian Camille
O'brien Fanny
Jing Wang Jing
Original Assignee
Alexion Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals, Inc. filed Critical Alexion Pharmaceuticals, Inc.
Publication of BR112018073945A2 publication Critical patent/BR112018073945A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a divulgação fornece métodos de tratamento de miastenia grave mg) num indivíduo que necessite do mesmo por meio da administração, ao indivíduo, de uma substância que liga especificamente um componente complementar 5 (c5). em certas modalidades, a substância que liga especificamente c5 é uma proteína de ligação, como um anticorpo anti-c5.
BR112018073945-6A 2016-05-27 2017-05-15 métodos para tratamento de miastenia grave generalizada refratária BR112018073945A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662342321P 2016-05-27 2016-05-27
US62/342,321 2016-05-27
US201662346168P 2016-06-06 2016-06-06
US62/346,168 2016-06-06
US201762489240P 2017-04-24 2017-04-24
US62/489,240 2017-04-24
US201762500643P 2017-05-03 2017-05-03
US62/500,643 2017-05-03
PCT/US2017/032767 WO2017205101A1 (en) 2016-05-27 2017-05-15 Methods for treatment of refractory generalized myasthenia gravis

Publications (1)

Publication Number Publication Date
BR112018073945A2 true BR112018073945A2 (pt) 2019-02-26

Family

ID=60412593

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018073945-6A BR112018073945A2 (pt) 2016-05-27 2017-05-15 métodos para tratamento de miastenia grave generalizada refratária

Country Status (11)

Country Link
US (2) US20170342139A1 (pt)
EP (2) EP3909609A1 (pt)
JP (2) JP2019517473A (pt)
KR (1) KR20190012199A (pt)
CN (1) CN109475630A (pt)
AU (1) AU2017269839A1 (pt)
BR (1) BR112018073945A2 (pt)
CA (1) CA3024618A1 (pt)
MX (1) MX2018014560A (pt)
RU (1) RU2018141451A (pt)
WO (1) WO2017205101A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3024618A1 (en) * 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
JP7102353B2 (ja) 2016-06-14 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｃ５抗体及びそれらの使用
WO2019118556A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
JP2022500427A (ja) * 2018-09-17 2022-01-04 国立大学法人京都大学 肝傷害又は肝不全の処置のための抗ｃ５剤の投与
WO2020106724A1 (en) * 2018-11-20 2020-05-28 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis in pediatric patients
MX2021009789A (es) * 2019-02-14 2021-11-17 Alexion Pharma Inc Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de miastenia gravis generalizada.
WO2021026160A1 (en) * 2019-08-05 2021-02-11 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis with eculizumab

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
JP4021194B2 (ja) 2001-12-28 2007-12-12 シャープ株式会社 薄膜トランジスタ装置の製造方法
US9415102B2 (en) * 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US7807378B2 (en) * 2005-12-29 2010-10-05 Industrial Technology Research Institute (Itri) Method of diagnosing myasthenia gravis and kits therefor
MX2011001371A (es) 2008-08-05 2011-06-16 Novartis Ag Composiciones y metodos para anticuerpos que se dirigen a la proteina de complementos c5.
CN102271703B (zh) * 2008-11-10 2015-09-16 阿雷克森制药公司 用于治疗补体相关障碍的方法和组合物
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
CA3024618A1 (en) * 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
US20190328854A1 (en) * 2016-08-29 2019-10-31 The Cleveland Clinic Foundation C5 immunization for autologous anti-c5 antibody production

Also Published As

Publication number Publication date
JP2019517473A (ja) 2019-06-24
EP3463461A1 (en) 2019-04-10
US20210246196A1 (en) 2021-08-12
RU2018141451A3 (pt) 2020-09-21
MX2018014560A (es) 2019-08-12
CN109475630A (zh) 2019-03-15
EP3463461A4 (en) 2020-05-20
CA3024618A1 (en) 2017-11-30
JP2022126773A (ja) 2022-08-30
RU2018141451A (ru) 2020-06-29
WO2017205101A1 (en) 2017-11-30
KR20190012199A (ko) 2019-02-08
US20170342139A1 (en) 2017-11-30
EP3909609A1 (en) 2021-11-17
AU2017269839A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
BR112018073945A2 (pt) métodos para tratamento de miastenia grave generalizada refratária
EA202190485A1 (ru) Соединения, модулирующие fxr (nr1h4)
EA201791017A1 (ru) Гидроксисодержащие соединения, модулирующие fxr (nr1h4)
EA201892480A1 (ru) Соединения, модулирующие fxr (nr1h4)
CO2017012342A2 (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit)
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
BR112018000769A2 (pt) anticorpos específicos para tau hiperfosforilada e métodos para uso dos mesmos
MX2017007522A (es) Compuestos moduladores del receptor x farnesoide (frx) (receptor nr1h4) novedosos.
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
BR112016007112A2 (pt) Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
BR112017027549A2 (pt) anticorpo para cd40
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112017000671A2 (pt) moléculas com especificidade para cd79 e cd22
BR112017006520A2 (pt) métodos de tratamento do lúpus eritematoso sistêmico usando um anticorpo de domínio direcionado contra cd28
CO6670524A2 (es) Proteínas de unión de dominio variable dual que se unen a ngf y al menos a un blanco adicional, y métodos para hacer y usar dichas proteínas de unión
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
BR112018075644A2 (pt) anticorpos anti-cd98 e conjugados de anticorpo e fármaco
PH12016501366A1 (en) Novel anti-baff antibodies
BR112018067951A2 (pt) moléculas que se ligam a ilt7 e métodos de uso destas
EA201890080A1 (ru) Анализ модуляторов
EA201400447A1 (ru) АНТИТЕЛА К CD1d
BR112018072211A2 (pt) anticorpos anti tl1a e utilizações dos mesmos
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2670 DE 08-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.